Clinical trial · Observational
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective
NCT06389552CI-TRIAL-00076552recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- Day 1 to Week 88
- description
- Duration of survival before pancreatic cancer recurrence or death
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- Day 1 to Week 88
- description
- Duration of overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery * ECOG 0 or 1 * Scheduled to RO or R1 resection * Organ function capable of chemotherapy Exclusion Criteria: * FOLFIRINOX contraindications among the drug approval requirements * Palliative Therapy * Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
References
Publications (0)
Data not yet available
No reference posted for this study.